AVM
SPTX

Arch Venture Management’s Seaport Therapeutics SPTX Stock Holding History

Arch Venture Management’s Portfolio SPTX Stock Details SPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$137M Buy
+6,294,951
New +$111M 12.42% 4

Other funds holding SPTX

GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TGV
TRV GP VI Boston, Massachusetts $232M AUM 247.08% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Arch Venture Management's SPTX Position: Q2 2026 in Review

Arch Venture Management opened a new position in Seaport Therapeutics (SPTX) in Q2 2026: 6,294,951 shares worth $137M. The stake represents 12.42% of the portfolio and ranks #4 among its holdings.

47 funds tracked by Wall St. Rank hold SPTX as of Q2 2026.

  • Arch Venture Management held 6,294,951 shares of Seaport Therapeutics worth $137M as of Q2 2026.
  • Seaport Therapeutics was a new Arch Venture Management position in Q2 2026.
  • Seaport Therapeutics made up 12.42% of Arch Venture Management's portfolio in Q2 2026, its #4 holding.
  • 47 funds tracked by Wall St. Rank held Seaport Therapeutics as of Q2 2026.

Based on Arch Venture Management's 13F filing for Q2 2026, filed 14 Aug 2026.